Loading clinical trials...
Loading clinical trials...
A Prospective, Single-arm, Open-label, Multicenter Phase II Trial Evaluating the Efficacy and Safety of Ivosidenib Maintenance Therapy After Allogeneic Stem Cell Transplantation (alloSCT) in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Neoplasia (MD) Carrying an IDH1 Mutation
Conditions
Interventions
Ivosidenib 250 MG (milligram)
Locations
12
Germany
Universitätsklinikum Aachen
Aachen, Germany
Technische Universitaet Dresden, Medizinische Klinik und Poliklinik I
Dresden, Germany
Universitätsklinikum Essen
Essen, Germany
Martin-Luther-Universitaet Halle-Wittenberg
Halle, Germany
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
Universitätsklinikum Jena
Jena, Germany
Start Date
June 17, 2025
Primary Completion Date
October 1, 2029
Completion Date
February 1, 2030
Last Updated
July 2, 2025
NCT03520647
NCT06859424
NCT06994676
NCT07450872
NCT06158828
NCT04645199
Lead Sponsor
Technische Universität Dresden
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions